Gossamer Bio
GOSS
115 hedge funds and large institutions have $430M invested in Gossamer Bio in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 35 reducing their positions, and 25 closing their positions.
6% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 35
1.9% less ownership
Funds ownership: 71.83% → 69.94% (-1.9%)
7% less funds holding
Funds holding: 123 → 115 (-8)
14% less capital invested
Capital invested by funds: $501M → $430M (-$70.2M)
32% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 25
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
86% less call options, than puts
Call options by funds: $424K | Put options by funds: $3.11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
+$10.2M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$7.16M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$7.05M |
| 4 |
Millennium Management
New York
|
+$4.91M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$6.21M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.64M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.9M |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.66M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.34M |
GOSS Hedge Fund Activity: Q2 2021 in Review
115 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q2 2021, worth a combined $430M — down 14% from $501M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of GOSS and 17 opened new positions — a net loss of 8 holders — while 35 trimmed existing stakes and 33 added.
The largest buyer was Ally Bridge Group, opening a new position worth an estimated $10.2M. The largest seller was Nuveen, cutting an estimated $6.21M.
- 115 institutional investors held Gossamer Bio (GOSS) as of Q2 2021, down from 123 in Q1 2021.
- Funds reported $430M of Gossamer Bio stock for Q2 2021, down 14% quarter-over-quarter.
- 17 funds opened new Gossamer Bio positions in Q2 2021 and 25 closed out, a net change of -8 holders.
- The largest Gossamer Bio buyer in Q2 2021 was Ally Bridge Group, an estimated $10.2M added.
- The largest Gossamer Bio seller in Q2 2021 was Nuveen, an estimated $6.21M sold.
Based on aggregated 13F filings for Q2 2021.